Global Antisense & RNAi Therapeutics Market Segments

21 Sep, 2020

The global antisense &RNAi therapeutics market is expected to decline from $1.14 billion in 2019 to $1.11 billion in 2020 at a compound annual growth rate (CAGR) of -2.89%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.44 billion in 2023 at a CAGR of 9.23%. The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. However, the high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the market.

The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

Request For A Free Sample For The Global Antisense & RNAi Therapeutics Market Report:

The global antisense & RNAi therapeutics market is further segmented based on type and geography.
By Technology: RNA Interference, Antisense RNA
By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other
By Geography: The global antisense & RNAi therapeutics market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, the North American antisense & RNAi therapeutics market accounts for the largest share in the global antisense & RNAi therapeutics market.

Read More On The Report For The Global Antisense & RNAi Therapeutics Market At:

Trends In The Antisense & RNAi Therapeutics Market
Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years.
Antisense & RNAi Therapeutics Global Market Report 2020 is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market overviews, analyzes and forecasts antisense & RNAi therapeutics market size and growth for the global antisense & RNAi therapeutics market, antisense & RNAi therapeutics market share, antisense & RNAi therapeutics market players, antisense & RNAi therapeutics market size, antisense & RNAi therapeutics market segments and geographies, antisense & RNAi therapeutics market trends, antisense & RNAi therapeutics market drivers and antisense & RNAi therapeutics market restraints, antisense & RNAi therapeutics market’s leading competitors’ revenues, profiles and market shares. The antisense & RNAi therapeutics market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.